- Arthrogryposis, a rare congenital condition characterized by joint contractures and muscle weakness, is gaining increasing attention in pediatric and orthopedic care due to its lifelong impact on mobility and quality of life, prompting the development of early intervention programs, specialized surgical approaches, and advanced rehabilitative therapies in both hospital and outpatient settings
- The growing demand for effective arthrogryposis treatment is primarily driven by improved neonatal screening, enhanced access to genetic diagnostics, and greater awareness among healthcare providers and caregivers about multidisciplinary management strategies
- North America dominated the arthrogryposis market with the largest revenue share of 38.9% in 2024, supported by advanced healthcare infrastructure, higher healthcare spending, and an active research landscape, particularly in the U.S., where pediatric orthopedic centers and genetic research institutions are spearheading innovation in personalized care and novel surgical techniques
- Asia-Pacific is expected to be the fastest growing region in the arthrogryposis market during the forecast period due to growing healthcare investments, improving diagnostic capabilities, and increasing government focus on rare disease treatment
- Surgery segment dominated the arthrogryposis market with a market share of 43% in 2024, driven by its effectiveness in correcting joint deformities and enhancing mobility outcomes in moderate to severe cases
